-
公开(公告)号：EP4048309A1
公开(公告)日：2022-08-31
申请号：EP20878471.0
申请日：2020-10-23
发明人： WATKINS, Jeffry D. , DICKERSON, Cindy T. , ROJAS, Rafael , REISSMAN, Matthew , MCNEELEY, Patricia , BILSBOROUGH, Janine , HENKLE, Bradley , TARGAN, Stephan R.
IPC分类号： A61K39/395 , C07K16/24 , C07K16/28
-
2.发明公开
公开(公告)号：EP4294444A1
公开(公告)日：2023-12-27
申请号：EP22756949.8
申请日：2022-02-17
发明人： LUO, Allison , OTSUKI, Lauren , MANNING, Mark , PAYNE, Robert , LAURENT, Olivier , BILSBOROUGH, Janine , HENKLE, Bradley , TARGAN, Stephan R.
IPC分类号： A61K39/395 , C07K16/24 , A61P1/04
-
3.发明公开
公开(公告)号：EP3774897A1
公开(公告)日：2021-02-17
申请号：EP19796203.8
申请日：2019-04-26
发明人： BILSBOROUGH, Janine , MCGOVERN, Dermot P. , TARGAN, Stephan , POTDAR, Alka , WATKINS, Jeffry, D. , DICKERSON, Cindy, T.
IPC分类号： C07K16/24 , A61K39/395 , C12Q1/68
-
4.发明公开
公开(公告)号：EP4296285A2
公开(公告)日：2023-12-27
申请号：EP23192639.5
申请日：2019-04-26
发明人： BILSBOROUGH, Janine , MCGOVERN, Dermot P. , TARGAN, Stephan , POTDAR, Alka , WATKINS, Jeffry, D. , DICKERSON, Cindy, T.
IPC分类号： C07K16/28
摘要： Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
-
5.发明公开
公开(公告)号：EP4296285A3
公开(公告)日：2024-02-28
申请号：EP23192639.5
申请日：2019-04-26
发明人： BILSBOROUGH, Janine , MCGOVERN, Dermot P. , TARGAN, Stephan , POTDAR, Alka , WATKINS, Jeffry, D. , DICKERSON, Cindy, T.
IPC分类号： C12Q1/6883 , C07K16/24 , A61K39/395
摘要： Described herein are methods and systems for identifying subjects suitable for treatment with an inhibitor of CD30L activity or expression, such as an anti-CD30L antibody. Methods and systems disclosed herein identify subjects suitable for treatment based on a presence of a genotype that is indicative of a disease or condition in the subject for which an inhibitor of CD30L is a suitable treatment. Exemplary conditions include both Crohn's disease and primary sclerosing cholangitis. Compositions used to detect the genotypes described herein, and methods of using them are also provided.
-
公开(公告)号：EP4244251A1
公开(公告)日：2023-09-20
申请号：EP21892810.9
申请日：2021-11-11
发明人： KRUIDENIER, Laurens , SABRIPOUR, Mahyar , WATKINS, Jeffry D. , DICKERSON, Cindy T. , ROJAS, Rafael , REISSMAN, Matthew , MCNEELEY, Patricia , BILSBOROUGH, Janine , MCGOVERN, Dermot P. , LI, Dalin
IPC分类号： C07K16/24 , C07K16/28 , C12Q1/6883 , A61K39/395
-
公开(公告)号：EP3969621A1
公开(公告)日：2022-03-23
申请号：EP20806755.3
申请日：2020-05-13
发明人： KRUIDENIER, Laurens , SABRIPOUR, Mahyar , BILSBOROUGH, Janine , MCGOVERN, Dermot P. , LI, Dalin
IPC分类号： C12Q1/6883 , C12Q1/6876
-
公开(公告)号：EP4294443A1
公开(公告)日：2023-12-27
申请号：EP22756948.0
申请日：2022-02-17
发明人： LUO, Allison , LAURENT, Olivier , MUNOZ, Ernesto J. , BILSBOROUGH, Janine , HENKLE, Bradley , TARGAN, Stephan R. , MCGOVERN, Dermot P.
IPC分类号： A61K39/395 , C07K16/28 , A61P11/00
-
公开(公告)号：EP3270964A1
公开(公告)日：2018-01-24
申请号：EP16765597.6
申请日：2016-03-15
IPC分类号： A61K39/395 , A61P35/00 , C07K16/24
CPC分类号： C07K16/249 , A61K39/395 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24
摘要： The present invention describes methods for treating inflammatory disorders of the gastrointestinal tract, including but not limited to Inflammatory Bowel Disease (IBD), Crohn's Disease (CD), Ulcerative Colitis (UC) and/or medically refractory ulcerative colitis (MR-UC) using anti-IFNG therapy. The present invention also describes a process for patient risk stratification.
-
公开(公告)号：EP4285988A2
公开(公告)日：2023-12-06
申请号：EP23188250.7
申请日：2014-03-27
IPC分类号： A61P1/00
摘要： The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.014 秒)
